KALY – Kali Extracts Confirms Analyst Report On Cannabis Extract Biopharmaceutical Strategy Scheduled For Publication Next Week
KALY has just posted its 2019 YTD financials reporting 250% revenue growth.
Read More
Select Page
Posted by Invest In Weed | Aug 23, 2019
KALY has just posted its 2019 YTD financials reporting 250% revenue growth.
Read MorePosted by Invest In Weed | Aug 22, 2019
The products include hemp, a proprietary blend of hemp and kenaf that is specifically formulated for the hemp bioplastics industry.
Read MorePosted by Invest In Weed | Aug 22, 2019
The releases comes as an offer of a healthier option to consumers currently using the rechargeable pod battery.
Read MorePosted by Invest In Weed | Aug 22, 2019
With 98 % support, the debenture holders approved the repayment of the principal amount of the debentures of CDN $12,961,000.
Read MorePosted by Invest In Weed | Aug 21, 2019
Ontario Securities Commission has removed the Company from its list of defaulting reporting issuers.
Read MoreGet stock alerts, news & related alerts straight to your inbox!